Prosecution Insights
Last updated: November 12, 2026
Application No. 18/423,232

Treatment of chronic pruritic dermatoses

Final Rejection §DOUBLEPATENT
Filed
Jan 25, 2024
Priority
Jan 29, 2023 — provisional 63/441,823
Examiner
MARTIN, KEVIN STEPHEN
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cymabay Therapeutics Inc.
OA Round
2 (Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
98%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
124 granted / 161 resolved
+17.0% vs TC avg
Strong +21% interview lift
Without
With
+20.7%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
52 currently pending
Career history
203
Total Applications
across all art units

Office Action

§DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims and Response to Amendments The amendments filed June 18, 2026 have been acknowledged and entered. Claims 1-13 and 19-20 are pending. Information Disclosure Statements Acknowledgement is made of the Information Disclosure Statement filed on June 18, 2026. All references have been considered except where marked with a strikethrough. Reference A114 does not have date and has not been considered. Withdrawn Rejections Applicant is notified that any outstanding rejection or objection that is not expressly maintained in this Office Action has been withdrawn or rendered moot in view of Applicant’s amendments and/or remarks. Maintained Rejections Claims 1-13 and 19-20 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1-16 of copending Application No. 18/423,217 in view of Ko et al (Kidney Res Clin Pract. 2023 Jan;42(1), Published on-line May 4, 2022) The reasons for this rejection were set forth in the previous Office Action mailed March 19, 2026 and are incorporated herein by reference. Regarding new claims 19-20, Ko teaches IL-31 is associated with pruritus including atopic dermatitis (see page 12, biologics, an anti-IL-31 antibody has been shown to reduce pruritus in patients with atopic dermatitis). Claims 1-13 and 19-20 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-26 of copending Application No. 19/286,679 in view of Trivedi et al. (American Journal of Medicine, Vol 130, No 6, June 2017) (hereinafter “Trivedi”). The reasons for this rejection were set forth in the previous Office Action mailed March 19, 2026 and are incorporated herein by reference. Regarding new claims 19-20, Trivedi teaches atopic dermatitis as noted previously. As evidenced by Ko, IL-31 is associated with atopic dermatitis (see page 12, biologics). Response to Arguments Applicant’s arguments filed June 18, 2026 have been fully considered but they are not persuasive. Applicant states they request that these rejections be held in abeyance until the indication of allowable subject matter in one of these applications. This response is found not persuasive since a complete response to a nonstatutory double patenting (NSDP) rejection is either a reply by applicant showing that the claims subject to the rejection are patentably distinct from the reference claims or the filing of a terminal disclaimer in accordance with 37 CFR 1.321 in the pending application(s) with a reply to the Office action (see MPEP § 1490 for a discussion of terminal disclaimers). Such a response is required even when the nonstatutory double patenting rejection is provisional. As filing a terminal disclaimer, or filing a showing that the claims subject to the rejection are patentably distinct from the reference application’s claims, is necessary for further consideration of the rejection of the claims, such a filing should not be held in abeyance. Only objections or requirements as to form not necessary for further consideration of the claims may be held in abeyance until allowable subject matter is indicated. The rejections are still deemed proper and thus maintained. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN MARTIN whose telephone number is (571)270-0917. The examiner can normally be reached Monday - Friday 8 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. August 5, 2026 /K.S.M./Examiner, Art Unit 1624 /BRUCK KIFLE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jan 25, 2024
Application Filed
Mar 19, 2026
Non-Final Rejection mailed — §DOUBLEPATENT
Jun 18, 2026
Response Filed
Aug 10, 2026
Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788753
REPOSITIONING THE ANTI-LEPROSY DRUG CLOFAZIMINE AGAINST DRUG-RESISTANT MYELOMA AND PUTATIVE STEM-CELL SUBCLONES
3y 5m to grant Granted Nov 10, 2026
Patent 12790343
SOLID FORMS OF PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS
2y 6m to grant Granted Nov 10, 2026
Patent 12758629
N-ARYL SULFONAMIDE DERIVATIVES AS VACCINE ADJUVANT
4y 8m to grant Granted Oct 13, 2026
Patent 12746239
COMPOSITIONS AND METHODS COMPRISING ENDOTHELIN A RECEPTOR ANTAGONISTS AND ANDROGEN THERAPIES
4y 10m to grant Granted Sep 29, 2026
Patent 12747214
IMIDAZOLE-BASED SYNTHETIC LIPIDOIDS FOR IN VIVO MRNA DELIVERY INTO IMMUNE CELLS
4y 0m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
98%
With Interview (+20.7%)
Moderate
PTA Risk
Based on 161 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month